Selective Uptake and Sustained Expression of AAV Vectors Following Subcutaneous Delivery

Journal of Gene Medicine

Volumn 1, Issue 1, 1999, Pages 31-42

  Donahue, Brian A ^a   McArthur, James G ^a   Spratt, S Kaye ^a   Bohl, Delphine ^b   Lagarde, Catherine ^a   Sanchez, Lisa ^a   Kaspar, Brian A ^a   Sloan, Barbara A ^a   Lee, Ya Li ^a   Danos, Olivier ^c   Snyder, Richard O ^a  

^a CELL GENESYS INC   (United States)

^b INSTITUT PASTEUR   (France)

^c GÉNÉTHON   (France)

Author keywords

Adeno associated virus; Erythropoietin; Factor IX; Interferon; Muscle; Subcutaneous

Indexed keywords

ADENO-ASSOCIATED VIRUS; ESCHERICHIA COLI; MURINAE;

ALPHA2A INTERFERON; BLOOD CLOTTING FACTOR 9; RECOMBINANT ERYTHROPOIETIN;

ADENO ASSOCIATED VIRUS; ANIMAL; ARTICLE; BAGG ALBINO MOUSE; BIOSYNTHESIS; BLOOD; FEMALE; GENE EXPRESSION; GENE THERAPY; GENE VECTOR; GENETIC TRANSDUCTION; GENETICS; HUMAN; LACTOSE OPERON; METABOLISM; MOUSE; SKELETAL MUSCLE; SUBCUTANEOUS DRUG ADMINISTRATION; TIME; TISSUE DISTRIBUTION;

ANIMALS; DEPENDOVIRUS; ERYTHROPOIETIN, RECOMBINANT; FACTOR IX; FEMALE; GENE EXPRESSION; GENE THERAPY; GENETIC VECTORS; HUMANS; INJECTIONS, SUBCUTANEOUS; INTERFERON ALFA-2A; LAC OPERON; MICE; MICE, INBRED BALB C; MUSCLE, SKELETAL; TIME FACTORS; TISSUE DISTRIBUTION; TRANSDUCTION, GENETIC;

EID: 0032599998     PISSN: 1099498X     EISSN: None     Source Type: Journal    
DOI: 10.1002/(SICI)1521-2254(199901/02)1:1<31::AID-JGM3>3.0.CO;2-T     Document Type: Article

References (52)

1. Supersaxo A, Hein WR, Steffen H. Effect of molecular weight on the lymphatic absorption of water-soluble compounds following subcutaneous administration. Pharm Res 1990; 7: 167-169.
2. Gerrard AJ, Austen DEG, Brownlee GG. Subcutaneous injection of factor IX for the treatment of haemophilia B. Br J Haematol 1992; 81: 610-613.
3. Liles D, Landen CN, Monroe DM, et al. Extravascular administration of factor IX: Potential for replacement therapy of canine and human hemophilia B. Thromb Haemost 1997; 77: 944-948.
4. Macdougall IC, Roberts DE, Coles GA, Williams JD. Clinical pharmacokinetics of Epoetin (recombinant human erythropoietin). J Clin Pharmacol 1991; 20: 99-113.
5. Wills RJ. Clinical pharmacokinetics of interferons. J Clin Pharmacol 1990; 19: 390-399.
6. Setoguchi Y, Jaffe HA, Danel C, Crystal RG. Ex vivo and in vivo gene transfer to the skin using replication-deficient recombinant adenovirus vectors. J Invest Dermat 1994; 102: 415-421.
7. Lu B, Scott G, Goldsmith LA. A model for keratinocyte gene therapy: preclinical and therapeutic considerations. Proc Assoc Am Physicians 1996; 108: 165-172.
8. Yang Y, Ertl HCJ, Wilson JM. MHC Class I-restricted cytotoxic T lymphocytes to viral antigens destroy hepatocytes in mice infected with E1-deleted recombinant adenoviruses. Immunity 1994; 1: 433-332.
9. Yang Y, Nunes FA, Berencsi K, Gonczol E, Engelhardt JF, Wilson JM. Inactivation of E2a in recombinant adenoviruses improves the prospect for gene therapy in cystic fibrosis. Nat Genet 1994; 7: 362-369.
10. Gilgenkrantz H, Duboc D, Juillard V, et al. Transient expression of genes transferred in vivo into heart using first-generation adenoviral vectors: Role of the immune response. Hum Gene Ther 1995; 6: 1265-1274.
11. Afione SA, Conrad CK, Kearns WG, et al. In vivo model of adeno-associated virus vector persistence and rescue. J Virol 1996; 70: 3235-3241.
12. Ali RR, Reichel MB, Thrasher AJ, et al. Gene transfer into the mouse retina mediated by an adeno-associated viral vector. Hum Mol Genet 1996; 5: 591-594.
13. Clark KR, Sferra TJ, Johnson PR. Recombinant adeno-associated viral vectors mediate long-term transgene expression in muscle. Hum Gene Ther 1997; 8: 659-669.
14. Conrad CK, Allen SS, Afione SA, et al. Safety of single-dose administration of an adeno-associated virus (AAV)-CFTR vector in the primate lung. Gene Ther 1996; 3: 658-668.
15. Kaplitt MG, Leone P, Samulski RJ, et al. Long-term gene expression and phenotypic correction using adeno-associated virus vectors in the mammalian brain. Nat Gen 1994; 8: 148-154.
16. Kaplitt MG, Xiao X, Samulski RJ, et al. Long-term gene transfer in porcine myocardium after coromary infusion of an adeno-associated virus vector. Ann Thorac Surg 1996; 62: 1669-1676.
17. Kessler PD, Podsakoff GM, Chen X, et al. Gene delivery to skeletal muscle results in sustained expression and systemic delivery of a therapeutic protein. Proc Natl Acad Sci U S A 1996; 93: 14082-14087.
18. Lalwani AK, Walsh BJ, Reilly PG, Muzyczka N, Mhatre AN. Development of in vivo gene therapy for hearing disorders: Introduction of adeno-associated virus in the cochlea of the guinea pig. Gene Ther 1996; 3: 588-592.
19. McCown TJ, Xiao X, Li J, Breese GR, Samulski RJ. Differential and persistent expression patterns of CNS gene transfer by an adeno-associated virus (AAV) vector. Brain Res 1996; 713: 99-107.
20. Mandel RJ, Spratt SK, Snyder RO, Leff SE. Midbrain injection of recombinant adeno-associated virus encoding rat glial cell line-derived neurotrophic factor protects nigral neurons in a progressive 6-hydroxydopamine-induced degeneration model of Parkinson's disease in rats. Proc Natl Acad Sci U S A 1997; 94: 14083-14088.
21. Monahan P, Samulski R, Tazelaar J, et al. Direct intramuscular injection with recombinant AAV vectors results in sustained expression in a dog model of hemophilia. Gene Ther 1998; 5: 40-49.
22. Murphy J, Zhou S, Giese K, Williams L, Escobedo J, Dwarki V. Long-term correction of obesity and diabetes in genetically obese mice by a single intramuscular injection of recombinant adeno-associated virus encoding mouse leptin. Proc Natl Acad Sci U S A 1997; 94: 1391-13926.
23. Peel A, Zolotukhin S, Schrimsher GW, Muzyczka N, Reier PJ. Efficient transduction of green fluorescent protein in spinal cord neurons using adeno-associated virus vectors containing cell type-specific promoters. Gene Ther 1997; 4: 16-24.
24. Snyder RO, Miao CH, Patijn GA, et al. Persistent and therapeutic concentrations of human factor IX in mice after hepatic gene transfer of recombinant AAV vectors. Nat Genet 1997; 16: 270-276.
25. Xiao X, Li J, Samulski RJ. Efficient long-term gene transfer into muscle of immunocompetent mice by an adeno-associated virus vector. J Virol 1996; 70: 8098-8108.
26. Snyder RO, Spratt SK, Lagarde C, et al. Efficient and stable AAV-mediated transduction in the skeletal muscle of adult immunocompetent mice. Hum Gene Ther 1997; 8: 1891-1900.
27. Herzog RW, Hagstrom JN, Kung S-H, et al. Stable gene transfer and expression of human blood coagulation factor IX after intramuscular injection of recombinant adeno-associated virus. Proc Natl Acad Sci U S A 1997; 94: 5804-5809.
28. Sambrook J, Fritsch EF, Maniatis T. Molecular Cloning, a Laboratory Manual, Second Edition. Cold Spring Harbor, NY. Cold Spring Harbor Press, 1989.
29. Samulski RJ, Chang LS, Shenk T. Helper-free stocks of recombinant adeno-associated viruses: normal integration does not require viral gene expression. J Virol 1989; 63: 3822-3828.
30. Naldini L, Blomer U, Gallay P, et al. In vivo gene delivery and stable transduction of nondividing cells by a lentiviral vector. Science 1996; 272: 263-267.
31. Snyder RO, Xiao X, Samulski RJ. Production of recombinant adeno-associated viral vectors. In: Dracopoli N, Haines J, Krof B, et al., eds. Current Protocols in Human Genetics. New York: John Wiley and Sons, 1996.
32. Li J, Samulski RJ, Xiao X. Role for highly regulated rep gene expression in adeno-associated virus vector production. J Virol 1997; 71: 5236-5243.
33. Ferrari FK, Samulski T, Shenk T, Samulski RJ. Second-strand synthesis is a rate-limiting step for efficient transduction by recombinant adeno-associated virus vectors. J Virol 1996; 70: 3227-3234.
34. Carter BJ. The growth cycle of adeno-associated virus. In: Tijssen P, ed. Handbook of Parvoviruses-vol. 1. Boca Raton, FL: CRC Press, 1990: 155-158.
35. Allen J, Debelak D, Reynolds T, Miller A. Identification and elimination of replication-competent adeno-associated virus (AAV) that can arise by nonhomologous recombination during AAV vector production. J Virol 1997; 71: 6816-6822.
36. Kay MA, Landen CN, Rothenberg SR, et al. In vivo hepatic gene therapy: complete albeit transient correction of factor IX deficiency in hemophilia B dogs. Proc Natl Acad Sci U S A 1994; 91: 2353-2357.
37. Flannery JG, Zolotukhin S, Vaquero MI, La Vail MM, Muzyczka N, Hauswirth WW. Efficient photoreceptor-targeted gene expression in vivo by recombinant adeno-associated virus. Proc Natl Acad Sci U S A 1997; 94: 6916-6921.
38. Gribaudo G, Ravaglia S, Gaboli M, Gariglio M, Cavallo R, Landolfo S. Interferon-α inhibits the murine cytomegalovirus immediate-early gene expression by down-regulating NF-κB activity. J Virol 1995; 211: 251-260.
39. Jooss K, Yang Y, Fisher K, Wilson J. Transduction of dendritic cells by DNA viral vectors directs the immune response to transgene products in muscle fibers. J Virol 1998; 72: 4212-4223.
40. Alexander IE, Russell DW, Miller AD. DNA-damaging agents greatly increase the transduction of nondividing cells by adeno-associated virus vectors. J Virol 1994; 68: 8282-8287.
41. Fisher KJ, Gao GP, Weitzman MD, De Matteo R, Burda JF, Wilson JM, Transduction with recombinant adeno-associated virus for gene therapy is limited by leading-strand synthesis. J Virol 1996; 70: 520-532.
42. Miao C, Snyder R, Schowalter D, et al. The kinetics of rAAV integration in the liver. Nat Genet 1998; 19: 13-15.
43. McLaughlin SK, Collis P, Hermonat PL, Muzyczka N. Adeno-associated virus general transduction vectors: analysis of proviral structures. J Virol 1988; 62: 1963-1973.
44. Naffakh N, Danos O. Gene transfer for erythropoiesis enhancement. Mol Med Today 1996: 343-348.
45. Fisher KJ, Jooss K, Alston J, et al. Recombinant adeno-associated virus for muscle directed gene therapy. Nature Med 1997; 3: 306-312.
46. Koeberl DD, Alexander IE, Halbert CL, Russell DW, Miller AD. Persistent expression of human clotting factor IX from mouse liver after intravenous injection of adeno-associated virus vectors. Proc Natl Acad Sci U S A 1997; 94: 1426-1431.
47. 1-antitrypsin in dogs after autologous transplantation of retroviral transduced hepatocytes. Proc Natl Acad Sci U S A 1992; 89: 89-93.
48. Guo ZS, Wang L-H, Eisensmith RC, Woo SLC. Evaluation of promoter strength for hepatic gene expression in vivo following adenovirus-mediated gene transfer. Gene Ther 1996; 3: 802-810.
49. Baskar JF, Smith PP, Nilaver G, et al. The enhancer domain of the human cytomegalovirus major immediate-early promoter determines cell type-specific expression in transgenic mice. J Virol 1996; 70: 3207-3214.
50. Schmidt EV, Christophe F, Zeller R, Leder P. The cytomegalovirus enhancer: a pan-active control element in transgenic mice. Mol Cell Biol 1990; 10: 4406-4411.
51. Halbert CL, Alexander IE, Wolgamot GM, Miller AD. Adeno-associated virus vectors transduce primary cells much less efficiently than immortalized cells. J Virol 1995; 69: 1473-14799.
52. Scharfmann R, Axelrod JH, Verma IM. Long-term in vivo expression of retrovirus-mediated gene transfer in mouse fibroblast implants. Proc Natl Acad Sci U S A 1997; 88: 4626-4630.